Search
oblimersen (Bcl-2 antisense)
Indications:
- adjunctive agent used with dacarbazine for treatment of melanoma
- benefits patients with normal baseline serum LDH levels
Adverse effects:
1) neutropenia, severe neutropenia (21%)
2) thrombocytopenia, severe thrombocytopenia (16%)
3) no increase in serious infections or bleeding
Mechanism of action:
1) 18-base antisense oligonucleotide that downregulates Bcl-2 expression & increases chemotherapy-induced apoptosis
2) increases median overall survival, 11.4 vs 9.7 months in patients with normal baseline serum LDH levels
General
antineoplastic agent (chemotherapeutic agent)
oligonucleotide
References
- Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M,
Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P,
Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group.
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in
patients with advanced melanoma: the Oblimersen Melanoma Study
Group.
J Clin Oncol. 2006 Oct 10;24(29):4738-45. Epub 2006 Sep 11.
PMID: 16966688